Epigenetic modifications mediated by histone deacetylases (HDACs) play important roles in the mechanisms of different neurologic diseases and HDAC inhibitors (HDACIs) have shown promise in therapy. However, pharmacodynamic profiles of many HDACIs in the brain remain largely unknown due to the lack of validated methods for noninvasive imaging of HDAC expression-activity. In this study, dynamic PET/CT imaging was performed in 4 rhesus macaques using [ 
Introduction
The status of histone acetylation in the brain, that is regulated by cooperative functions of histone acetyl transferases (HATs) and histone deacetylases (HDACs), has received much attention during the last decade (Abel and Zukin, 2008; Jenuwein and Allis, 2001) . Epigenetic mechanisms involving modifications of histones has been implicated in the development of various neurodegenerative diseases, multiple sclerosis, and epilepsy (Janssen et al., 2010; Kazantsev and Thompson, 2008; Mai et al., 2009; Monti et al., 2009; Tsankova et al., 2007) . Histone deacetylase inhibitors (HDACIs) have shown efficacy in therapy of neurodegenerative diseases (Butler and Bates, 2006; Dietz and Casaccia, 2010; Sadri-Vakili and Cha, 2006) . HDACIs increase the expression of neuroprotective proteins, such as Hsp70 and Bcl-2 in the ischemic brain, which points to the therapeutic potential of HDACIs in stroke (Faraco et al., 2006) . In models of motor neuron disease, such as the amyotrophic lateral sclerosis, inhibition of HDACs resulted in a reduction of clinical symptoms (Ryu et al., 2005) . HDACIs have also shown promise in therapy of peripheral nerve damage (Cui et al., 2003) . The involvement of HDACs in the mechanisms of development of alcoholism (Pandey et al., 2008) and drug addiction (Crepaldi and Riccio, 2009; Renthal and Nestler, 2009 ) and the effects of HDACIs in these disorders have been demonstrated as well (Kalda et al., 2007; Sanchis-Segura et al., 2009) .
However, the pharmacodynamic (PD) profiles of several HDACIs in the brain are largely unknown, which complicates the optimization and individualization of treatment protocols. The PD effects on HDACIs is often assessed in surrogate tissues (i.e., peripheral blood mononuclear cells Ronzoni et al., 2005) by measuring the levels of acetylated histones, which does not necessarily correlate with therapeutic responses in the brain and other tissues (Chavez-Blanco et al., 2005; Kelly et al., 2005) . Also, it is not known whether there is a requirement for continuous inhibition of HDACs to achieve the optimal therapeutic effects and there are no predictive biomarkers for selection of patients who are most likely to respond to treatment with HDACIs (Kelly et al., 2005; Minucci and Pelicci, 2006) . The assessment of pharmacodynamics of HDACIs in CNS is complicated due to an unacceptable traumatism of microdialysis and biopsy procedures. Therefore, novel molecular imaging agents for visualization and quantification of HDAC activity in the brain are urgently needed to facilitate the development and clinical translation of novel HDACIs.
To address this need, we have been developing agents and methods for molecular imaging of pharmacodynamic effects of HDACIs using magnetic resonance spectroscopy (MRS) (Sankaranarayanapillai et al., 2006) . Also, we developed a novel radiolabeled HDAC substrate, the 6-( (Nishii et al., 2007) . Subsequently, [
18 F]FAHA PET with simplified pharmacokinetic (PK) modeling was used to assess SAHA-induced inhibition of HDAC activity in the brain of non-human primates (Reid et al., 2009 ).
In (Nishii et al., 2012 (Mukhopadhyay et al., 2006) . Decay-corrected yield was 11±2% and specific activity >2 GBq/mmol.
Assessment of substrate specificity of FAHA for different HDACs
In vitro enzyme assays were performed in a panel of classes I, II, III, and IV HDACs (BPS Bioscience, San Diego, CA) in the buffer: 25 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , and 0.1 mg/ml BSA, 10 ng of each HDAC enzyme and different concentrations of non-radilabeled FAHA. Reactions were carried out for 30 min at 30°C and products determined by HPLC using Ascentis RP-amide 7×300 mm column (Supelco), MeCN/0.02 mM O-phosphoric acid as mobile phase at 0.6 ml/min with UV detection of the cleaved product (hexanoic anilide) at 240 nm. The Km, Vmax and Kcat parameters were determined using software GraphPad Prism v4 (GraphPad Software, La Jolla, CA).
Management of non-human primates
All studies were performed under a protocol approved by the Institutional Animal Care and Use Committee of the University of Texas M.D. Anderson Cancer Center (UTMDACC). Four rhesus macaques (2 males and 2 females) under anesthesia were studied. Prior to imaging studies, the animals were fasted overnight, but had a free access to water. The animals were premedicated with atropine sulfate 0.04 mg/kg intramuscularly (i.m.) and sedated with ketamine 10-15 mg/kg i.m., followed by intubation and inhalation anesthesia with isoflurane 1-3% in oxygen via Excel 210 SE (Ohmeda). Then, the animals were cannulated in both saphenous veins: one, for injection of 18 F-FAHA or 18 F-FACE; the other, for blood sampling. Body temperature was maintained at 37°C with warming blanket (Model 505; Arizant Healthcare). Electrocardiogram, respiration, blood pressure and oxygenation were monitored with Solar 8000 (Marquette Medical Systems, WI).
MRI/PET/CT imaging studies MR imaging was performed on an 8-channel 1.5 T HDx scanner with CRM gradient subsystem (GE Healthcare, WI). T1-weighted images were acquired using an inversion recovery-prepared 3D fast spoiled gradient recalled echo (FSPGR) sequence (12 degree flip angle, TE/TR=4.9/ 10.4 ms, 18×18 cm FOV, 320×320 acquisition matrix,1.2-mm sections reconstructed every 0.6 mm, ±21 kHz bandwidth). T2-weighted images were acquired using a 3D T2 CUBE imaging sequence (TE/TR= 128/3000 ms, echo train length: 120, 18×18 cm FOV, 320×320 acquisition matrix, 1.2-mm sections reconstructed every 0.6 mm, ±31 kHz bandwidth). The T1-and T2-weighted images were reformatted into 1-mm thick contiguous images in three orthogonal planes.
PET/CT imaging was performed using Discovery STE16 (GE Healthcare, WI); the axial fields-of-view (FOV) of CT and PET were 50 cm and 70 cm, respectively. Transmission CT images of the head was used to verify the accuracy of positioning to match the prior MR images. The first PET imaging study was performed with 18 F-FACE (5.95± 0.96 mCi in 5 ml saline) administered as a steady bolus over 1 min, as described before (Nishii et al., 2012; Tian et al., 2011) . Dynamic PET images were acquired over 30 min. The second PET imaging study with [ . PET images were reconstructed from the list-mode data for the following time frames: 12×15 s, 6×30 s, and 25×60 s; (total of 33 frames/study) using an iterative algorithm VuePoint (GE Healthcare) with 2 iterations, 28 subsets, 20 cm DFOV, kernel width 2.0 mm FWHM and a standard z-axial filter, with scatter and attenuation corrections. PET images had a resolution of 128×128 voxels with spatial resolution of 4.4 mm full width at half maximum (FWHM) and slice thickness of 3.25 mm.
MR images were coregistered to the corresponding PET/CT images summed from dynamic 30 min scans using a rigid transformation algorithm and a normalized mutual method after running a re-slicing process with software PMOD version 3.1 (PMOD Technologies, Zurich, Switzerland). Volumes-of-interest (VOI) for carotid artery, whole brain, n. accumbens and cerebellum were defined and time activity curves (TACs) generated.
Assessment of radiolabeled metabolites in blood plasma
The radioactivity concentration in the whole blood and plasma was assayed using a gamma counter (Cobra, Packard, CT). Plasma was extracted from heparinized blood samples (0.5 ml) with 3× volumes of acetonitrile and analyzed with radio-HPLC: 1100 HPLC (Agilent, Santa Clara, CA), UV and radioactivity detectors (Bioscan Inc., Washington, DC); Supelcogel C-610H column (Sigma-Aldrich, MO); mobile phase: 35% MeCN/Phosphoric acid in water at 0.6 ml/min. and plotted against time. The average plasma-to-blood radioactivity concentration ratio was calculated from blood samples obtained at different times post 18 F-FAHA administration and used for quantification of PET images, as described further.
Assessment of [ 18 F]FAHA-derived radiolabeled metabolites in the brain
This study was performed under the approval of the RIKEN Kobe Institute Animal Committee (MAH21-13), Kobe, Japan. One rhesus macaque was anesthetized with ketamine (10 mg/kg) and atropine (0.08 mg/kg) for placement of an i.v. catheter. Then, the animal was placed into the specialized primate chair, and after recovery from anesthesia, [
18 F]FAHA (37 MBq/kg) was administered as a quick bolus injection. Three minutes later, the animal was deeply anesthetized by a bolus of pentobarbital (30 mg/kg, i.v.) and heparinized (1000U i.v.). At 7 min post injection of [ 18 F]FAHA, the intracardiac perfusion with ice-cold 10 mM PBS was performed through the left ventricle and the animal sacrificed. The whole brain was quickly removed (within 10 min), sliced into 6 mm thick sections, and frozen in liquid nitrogen; different structures of the brain were dissected, weighed, and homogenized using an equal amount of ice-cold ddH 2 O. Brain tissue homogenates were mixed with 3 volumes of acetonitrile for 30 s and centrifuged at 10,000 ×g for 2 min at 4°C. The supernatants were spotted (2 μl/spot) on a TLC plate silica 60 (Merck, Germany), developed using acetonitrile/water/ammonia hydroxide (90/9/1), and quantified by the imaging plate analyzer FLA-7000IR (Fujifilm, Japan).
PET image analyses and pharmacokinetic modeling
First, to calculate dynamic PET image-derived input functions for [ 18 F]FAHA and [
18 F]FACE in blood plasma, the TAC was measured from the region of interest placed on the carotid artery and corrected using the mean plasma-to-whole blood radioactivity concentration ratio measured in blood samples (as described above (Fonnum et al., 1997; Proudfoot et al., 2006) . However, there is no effective catabolism of fluoroacetyl-coA, fluorooxalate, and fluorocitrate back to fluoroacetate, which accounts for its neurotoxicity at pharmacologically relevant doses (Fonnum et al., 1997; Proudfoot et al., 2006) . Therefore, the rate constant k4 FACE was set to zero. 
Compartmental modeling, pharmacokinetic analyses, and generation of pixel-by-pixel parametric images were accomplished using PMOD 3.1 software (PMOD Technologies Ltd., Zurich, Switzerland). Statistical analyses of data were performed using GraphPad Prism 4 (GraphPad software, La Jolla, CA, USA). 
Immunohistochemical staining of class I and II HDACs and acetyl-histones in the brain
Formalin-fixed, paraffin-embedded brain samples were cut (5 μm), deparaffinized, rehydrated, and microwaved in 10 mM citrate buffer (pH 6.0) at 95°C for 10 min; then incubated in 3% H 2 O 2 for 15 min and blocked with 1.5% rabbit or goat serum in PBS for 60 min. Then, sections were incubated overnight at 4°C with primary antibodies diluted 1:50 in 1% TBS: HDACs 1, 2, 3, 5, 7, 8, and 9 (Santa Cruz Biotech., CA); HDACs 4 and 6 (Cell Signaling Technology, MA), HDACs 10-11 (Sigma-Aldrich, MO); and AH2A-K5, AH2B-K5, AH2B-K20, AH3-K9, AH3-K18, AH3-K23, AH4-K8, and AH4-K12 (Cell Signaling, MA). Biotinylated secondary antibodies and 3,3-diaminobenzidine from the Vectastain Elite kit (Vector Laboratories, CA) were used according to the manufacturer's protocol. The sections were counterstained with hematoxylin and evaluated on BX51 microscope, equipped with DP71 digital camera (Olympus, Japan).
Results

Substrate specificity of FAHA to class IIa HDAC enzymes
In vitro enzymatic studies demonstrated that FAHA has higher substrate specificity for class IIa HDACs with Kcat values two orders of magnitude higher than for other classes of HDACs (Fig. 2) .
The time course of [
18 F]FACE and radiolabeled metabolites in blood and brain
After intravenous administration of [
18 F]FACE, the clearance of radioactivity from plasma followed a bi-exponential kinetics with the fast phase between 3 and 18 min with a half-life of 4 min, followed by a slow phase with a half-life of about 4 h (Fig. 3A) F]FAHA, the clearance of total radioactivity from plasma followed a bi-exponential kinetics with the fast phase during the first 3 min with a half-life of 30 s followed by a slow phase with half-life of about 8 min (Fig. 5A) ).
and especially in the vermis (Fig. 4C) . Parametric images of unidirectional rate (Ki) of [
18 F]FAHA-derived radioactivity accumulation in the brain, generated using the newly developed compartmental model, enhanced these observations (Fig. 4D) (Fig. 4E-J Table 2 ). Higher IC50 values for SAHA were observed in periaqueductal gray, cerebellum, n. accumbens, inferior colliculus, putamen, and amygdala. Relatively lower SAHA IC50 values were observed in the hippocampus, temporal cortex, and white matter.
Expression of class I and II HDACs and acetylation status of histones in different brain structures
In the n. accumbens (SI Appendix, Fig. S3 ), HDACs class I and class IIa, were highly expressed, predominantly in the neurons, except for HDAC 7, which was expressed in microvessels. In particular, high levels of HDACs 4 and 5 expression were observed in neurons. HDAC 6 was expressed in neurons and glia, whereas HDAC 10 was expressed predominantly in glial cells. HDAC 11 was highly expressed both, in neurons and glia (Fig. S4 ). H3-K18 was most deacetylated, while H2B-K20 and H4K-12 were most acetylated.
In the hippocampus (SI Appendix, Figs. S5-9), HDACs 2, 3, and 10 were expressed at high levels, especially in the dentate gyrus (DG) neurons. HDAC 5 was moderately expressed in CA2 and CA3 neurons, whereas HDACs 1 and 4 were expressed the least (SI Appendix, Figs. S6, S7). HDAC 6 was moderately expressed in CA1 and DG (SI Appendix, Figs. S5, S9). Moderate-to-high levels of HDAC 11 were observed throughout hippocampus (SI Appendix, Fig. S5 ). H3-K18 was the most acetylated, while H3-K9 and H3-K23 were the most deacetylated throughout the hippocampus (SI Appendix, Fig. S11-14) .
In the brain cortex (SI Appendix, Fig. S15 ), the level of expression of class IIa HDACs was notably lower than that of the class I HDACs, and lower than the expression of HDAC class IIa in the n. accumbens. HDAC 6 was expressed in the neurons and glia, whereas HDAC 10 was expressed predominantly in the glia. HDAC 11 was expressed both, in neurons and glia. H3-K18 was the most acetylated, while H3-K9 and H3-K23 were the most deacetylated (SI Appendix, Fig. S16 ).
In the cerebellum (SI Appendix, Fig. S17 ), amongst class I HDACs, high levels of HDACs 1 and 2 were observed in Bergmann microglial cells, whereas high levels of 8 expression were observed in most of the cell types. Amongst HDAC class IIa, high levels of HDACs 4 and 9 expression was observed in Purkinje cells, whereas HDAC 5 was moderately expressed in granular and molecular layer cells. HDAC 7 was expressed in microvascular endothelial cells and as granules localized in the pinceau terminals of basket neurons, embracing the Purkinje cell bodies. Amongst HDACs class IIb, HDAC 6 was expressed predominantly in the Purkinje cells, whereas HDAC 10 was expressed in granular and molecular layer cells. HDAC 11 (class IV) was moderately expressed in Brenner microglial cells. The acetylation of H2A-K5, H2B-K20, H3-K9, H3-K18, H3-K23, and H4-K12, was almost non-detectable in the vast majority of Purkinge cells. Low acetylation levels of H3-K23 were observed in all cells in the cerebellum, whereas the lowest levels of H3-K9 acetylation was observed in the granular layer cells. Highest levels of acetylation of other histone lysine residues were observed in cells of the molecular layer (SI Appendix, Fig. S18 ).
The results of qualitative assessment of expression of individual HDAC isoforms in different brain structures are summarized in SI Appendix, Table S1 . The acetylation status of certain lysine residues on different histones is summarized in SI Appendix, Table S2 .
Discussion
There is increasing evidence that HDAC-mediated epigenetic regulation is involved in neurogenesis, neuronal plasticity, learning, memory formation and recall, as well as CNS disorders including cognitive dysfunction, depression, addiction, and schizophrenia and several neurodegenerative diseases (for review : Fischer et al., 2010; Jiang et al., 2008; Renthal and Nestler, 2009; Tsankova et al., 2007) . Development of novel isotype-selective HDAC inhibitors and the assessment of their efficacy for therapy of different brain diseases (Thomas, 2009 ) could be facilitated by PET imaging with HDAC class and isotype-selective agents.
In this study, we determined that [
18 F]FAHA exhibits preferential substrate affinity to class IIa enzymes (HDACs 4, 5, 7, and 9), which is consistent with other reports demonstrating that trifluoro substitutions in the methyl group of acetyl moiety of acetyl-lysine, increase substrate specificity for the class IIa HDACs (Jones et al., 2008; Lahm et al., 2007) .
To quantify PET/CT/MR images of [ 18 F]FAHA accumulation in the brain we developed a new pharmacokinetic compartmental model that is substantially different than previously reported simple oneand two-compartmental models (Reid et al., 2009) . We demonstrated that due to high lipophilicity, [ 18 F]FAHA crosses the cell membranes and BBB by non-facilitated diffusion, as evidenced by high influx and efflux rate constants k1 FAHA and k2 FAHA , respectively. In contrast, the influx and efflux rate constants of [ 18 F]FACE are 10 to 20 fold smaller, because fluoroacetate is a hydrophilic molecule and does not cross membranes easily and its transport across the blood-brain-barrier and across glial and neuronal cell membranes is rate-limited by H + coupled monocarboxylate transporters (MCTs). The MCT1 is expressed predominantly by the brain microvascular endothelial and glial cells, whereas the MCT2 is expressed predominantly in neurons, especially in the cortex, hippocampus, and cerebellum (Pierre and Pellerin, 2005 (Carrell et al., 1970; Lauble et al., 1996) (Clarke, 1991; Goncharov et al., 2006; Peters and Wakelin, 1953 (Hendricks, et al., 2011; Zeglis, et al., 2011) and [ 11 C]MS-275 (Hooker, et al., 2010 F]FAHA accumulation observed in n. accumbens, and cerebellum were associated with high expression levels of HDACs 4 and/or 5. These observations are important, because HDACs 4 and 5 in n. accumbens are known to play important roles in the development of drug addiction (Kumar et al., 2005; Renthal et al., 2007) . Consistent with previous reports (Broide et al., 2007) , in this study moderate levels of HDAC 5 expression and hypoacetylation of H3 and H4 were observed in the hippocampus, especially in CA2 and CA3 neurons, but lower levels in neurons of the dentate gyrus. HDAC 5 expression in hippocampal neurons plays an important role in the mechanism of depression (Tsankova et al., 2006) . A stimulation inducing long-term depression causes HDAC 5-mediated deacetylation of H3 and H4 in the C/EBP gene promoter and prevents the establishment of long-term potentiation (Guan et al., 2002 (Majdzadeh et al., 2008) . Expression of HDAC 5 observed in cerebellar granule cells is also consistent with its neuroprotective functions (Bolger and Yao, 2005; Chawla et al., 2003; Linseman et al., 2003) . Noteworthy, is an almost complete deacetylation of lysine residues of histone proteins (H2A-K5, H2B-K20, H3-K9, H3-K18, H3-K23, and H4-K12) observed in Purkinje cells in the cerebellum, which warrants further studies to elucidate the significance of these new findings.
In contrast to n. accumbens, hippocampus, and cerebellum, much lower levels of class IIa HDAC expression and lower activity and a more pronounced acetylation of histones were observed in the brain cortex and white matter, which explains the lower accumulation of [ . Consistent with the results of IHC studies, lower IC50 values for SAHA were determined for brain regions expressing lower levels of class IIa HDACs (i.e., cortex), as compared to higher IC50 values of SAHA for the brain structures expressing class IIa HDACs at higher levels (i.e., n. accumbens, cerebellum).
Conclusions
Taken together, these results indicate that the unidirectional accumulation of [ 
